samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > over the counter and through the woods: china's otc market in transition
PUBLICATIONS
European Biopharmaceutical Review

Over the Counter and Through the Woods: China's OTC Market in Transition

Winters in Shanghai can be particularly tough - cold grey days marked with heavy wind and rain. In a crowded city of 16 million, there are likely to be lots of colds and flu, and much like anywhere these sufferers will want fast and effective relief. Unless symptoms are severe, most Chinese will look to prescription-free OTC drugs purchased from a retail pharmacy, to ease their pain. This article looks at factors which signal growth in this sector, current obstacles and barriers which might preclude foreign participation and what changes are afoot to allow for a more open and competitive market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ben Goodger, Head of the Asia Commercial Intellectual Property Group at Rouse & Co, Shanghai

Ben Goodger is an Executive of Rouse & Co International, specialists in intellectual property management and protection worldwide. Ben won an Open Exhibition to Keble College in 1981 and completed his Articles with Frere Cholmeley Bischoff. After qualification, he joined the city law firm of Denton Hall.
In 1993 he joined Dallas Brett and was made a Partner in 1996, before moving to Rouse & Co/Willoughby & Partners in 1997. His practice can broadly be split into three main areas: computers and Internet related law, 'hi-tech' (biotechnology, technology transfer, patents) and trademark protection/brand management. He re-located to Rouse & Co's Shanghai office in August 2002 to head up the firm's Asia Commercial Intellectual Property Group.

spacer
Ben Goodger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

H&T Presspart announces partnership with BIOCORP for the InspairTM digital technology

H&T Presspart (a division of the German based Heitkamp & Thumann Group), announces today that a new partnership deal has been signed with BIOCORP, a French based company specialised in the development and manufacture of medical devices and connected healthcare solutions, whereby H&T Presspart is licensed to sell and promote BIOCORPís InspairTM smart add-on device for metered-dose inhalers.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement